CRISPR/Cas and Gene Therapy: An Overview

Luis María Vaschetto

DOI: https://doi.org/10.1201/9781003088516-5

2021-12-15

Abstract:Gene therapy involves the introduction of exogenous nucleic acids into target patient’s cells to treat diseases linked to aberrant gene expression patterns. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas9) adaptive immunity system was repurposed to edit eukaryotic genomes in order to correct and/or replace defective genes associated with disease and disorders. However, several technical limitations hinder the use of the CRISPR-Cas9 genome editing system for gene therapy in humans. This chapter summarizes these limitations and provides several showcase examples that may help to better understand how CRISPR-Cas9 strategies can be used for therapeutic purposes. Gene therapy involves the introduction of exogenous nucleic acids into target patient's cells to treat diseases linked to aberrant gene expression patterns. Traditional gene therapy approaches are based on the use of viral vectors and transgene expression to replace defective proteins, but these methods have raised several concerns associated with insertional mutagenesis, use of replication-deficient viral vectors, high immunogenicity and cytotoxicity effects. Retinal cells are an interesting target in CRISPR/Cas gene therapy due to the small volume of retinal tissue and its self-contained nature, both being beneficial features to avoid undesired systemic side effects. Alzheimer’s disease is a neurodegenerative disease and the most common cause of dementia due to the loss of memory and impairment of cognitive functions.